ES2773834T5 - Métodos y composiciones para tratar la depresión usando ciclobenzaprina - Google Patents
Métodos y composiciones para tratar la depresión usando ciclobenzaprina Download PDFInfo
- Publication number
- ES2773834T5 ES2773834T5 ES12755254T ES12755254T ES2773834T5 ES 2773834 T5 ES2773834 T5 ES 2773834T5 ES 12755254 T ES12755254 T ES 12755254T ES 12755254 T ES12755254 T ES 12755254T ES 2773834 T5 ES2773834 T5 ES 2773834T5
- Authority
- ES
- Spain
- Prior art keywords
- cyclobenzaprine
- day
- dose
- depression
- administered
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- JURKNVYFZMSNLP-UHFFFAOYSA-N cyclobenzaprine Chemical compound C1=CC2=CC=CC=C2C(=CCCN(C)C)C2=CC=CC=C21 JURKNVYFZMSNLP-UHFFFAOYSA-N 0.000 title claims description 76
- 229960003572 cyclobenzaprine Drugs 0.000 title claims description 75
- 238000000034 method Methods 0.000 title claims description 16
- 239000000203 mixture Substances 0.000 title description 22
- 208000001640 Fibromyalgia Diseases 0.000 claims description 7
- 239000000935 antidepressant agent Substances 0.000 claims description 4
- 239000010409 thin film Substances 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 description 20
- 238000013270 controlled release Methods 0.000 description 15
- 239000003826 tablet Substances 0.000 description 15
- 238000009472 formulation Methods 0.000 description 12
- 238000010521 absorption reaction Methods 0.000 description 9
- 239000003814 drug Substances 0.000 description 9
- 208000024891 symptom Diseases 0.000 description 9
- 208000019901 Anxiety disease Diseases 0.000 description 7
- 230000036506 anxiety Effects 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- 239000000499 gel Substances 0.000 description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
- 229920002261 Corn starch Polymers 0.000 description 5
- 108010081668 Cytochrome P-450 CYP3A Proteins 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 5
- 239000008120 corn starch Substances 0.000 description 5
- 229940099112 cornstarch Drugs 0.000 description 5
- 239000007903 gelatin capsule Substances 0.000 description 5
- 239000008187 granular material Substances 0.000 description 5
- 239000000902 placebo Substances 0.000 description 5
- 229940068196 placebo Drugs 0.000 description 5
- 208000019116 sleep disease Diseases 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 108700028369 Alleles Proteins 0.000 description 4
- UGJMXCAKCUNAIE-UHFFFAOYSA-N Gabapentin Chemical compound OC(=O)CC1(CN)CCCCC1 UGJMXCAKCUNAIE-UHFFFAOYSA-N 0.000 description 4
- 239000001961 anticonvulsive agent Substances 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 230000008030 elimination Effects 0.000 description 4
- 238000003379 elimination reaction Methods 0.000 description 4
- 230000009246 food effect Effects 0.000 description 4
- 239000011159 matrix material Substances 0.000 description 4
- 238000007911 parenteral administration Methods 0.000 description 4
- 229940124834 selective serotonin reuptake inhibitor Drugs 0.000 description 4
- 239000012896 selective serotonin reuptake inhibitor Substances 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- 102000004328 Cytochrome P-450 CYP3A Human genes 0.000 description 3
- 208000020401 Depressive disease Diseases 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 229940121991 Serotonin and norepinephrine reuptake inhibitor Drugs 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 239000000951 adrenergic alpha-1 receptor antagonist Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 206010016256 fatigue Diseases 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 239000002502 liposome Substances 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- 208000024714 major depressive disease Diseases 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 239000003775 serotonin noradrenalin reuptake inhibitor Substances 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 108010074922 Cytochrome P-450 CYP1A2 Proteins 0.000 description 2
- 102100026533 Cytochrome P450 1A2 Human genes 0.000 description 2
- 108010052832 Cytochromes Proteins 0.000 description 2
- 102000018832 Cytochromes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N Iron oxide Chemical compound [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 208000007101 Muscle Cramp Diseases 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 208000005392 Spasm Diseases 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- KJADKKWYZYXHBB-XBWDGYHZSA-N Topiramic acid Chemical compound C1O[C@@]2(COS(N)(=O)=O)OC(C)(C)O[C@H]2[C@@H]2OC(C)(C)O[C@@H]21 KJADKKWYZYXHBB-XBWDGYHZSA-N 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 230000001773 anti-convulsant effect Effects 0.000 description 2
- 229940125681 anticonvulsant agent Drugs 0.000 description 2
- 229960003965 antiepileptics Drugs 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 239000002876 beta blocker Substances 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 229960000623 carbamazepine Drugs 0.000 description 2
- FFGPTBGBLSHEPO-UHFFFAOYSA-N carbamazepine Chemical compound C1=CC2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 FFGPTBGBLSHEPO-UHFFFAOYSA-N 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 229960004341 escitalopram Drugs 0.000 description 2
- WSEQXVZVJXJVFP-FQEVSTJZSA-N escitalopram Chemical compound C1([C@]2(C3=CC=C(C=C3CO2)C#N)CCCN(C)C)=CC=C(F)C=C1 WSEQXVZVJXJVFP-FQEVSTJZSA-N 0.000 description 2
- 235000021471 food effect Nutrition 0.000 description 2
- 229960002870 gabapentin Drugs 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 238000000227 grinding Methods 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000007913 intrathecal administration Methods 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 229960001848 lamotrigine Drugs 0.000 description 2
- PYZRQGJRPPTADH-UHFFFAOYSA-N lamotrigine Chemical compound NC1=NC(N)=NN=C1C1=CC=CC(Cl)=C1Cl PYZRQGJRPPTADH-UHFFFAOYSA-N 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- 239000000693 micelle Substances 0.000 description 2
- 239000004005 microsphere Substances 0.000 description 2
- 229960001816 oxcarbazepine Drugs 0.000 description 2
- CTRLABGOLIVAIY-UHFFFAOYSA-N oxcarbazepine Chemical compound C1C(=O)C2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 CTRLABGOLIVAIY-UHFFFAOYSA-N 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- IENZQIKPVFGBNW-UHFFFAOYSA-N prazosin Chemical compound N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(CC1)CCN1C(=O)C1=CC=CO1 IENZQIKPVFGBNW-UHFFFAOYSA-N 0.000 description 2
- 229960001289 prazosin Drugs 0.000 description 2
- 229960001233 pregabalin Drugs 0.000 description 2
- AYXYPKUFHZROOJ-ZETCQYMHSA-N pregabalin Chemical compound CC(C)C[C@H](CN)CC(O)=O AYXYPKUFHZROOJ-ZETCQYMHSA-N 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 208000022925 sleep disturbance Diseases 0.000 description 2
- 230000003860 sleep quality Effects 0.000 description 2
- 210000000813 small intestine Anatomy 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- AEQFSUDEHCCHBT-UHFFFAOYSA-M sodium valproate Chemical compound [Na+].CCCC(C([O-])=O)CCC AEQFSUDEHCCHBT-UHFFFAOYSA-M 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 229910001220 stainless steel Inorganic materials 0.000 description 2
- 239000010935 stainless steel Substances 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 229960001918 tiagabine Drugs 0.000 description 2
- PBJUNZJWGZTSKL-MRXNPFEDSA-N tiagabine Chemical compound C1=CSC(C(=CCCN2C[C@@H](CCC2)C(O)=O)C2=C(C=CS2)C)=C1C PBJUNZJWGZTSKL-MRXNPFEDSA-N 0.000 description 2
- 229960004394 topiramate Drugs 0.000 description 2
- 229940102566 valproate Drugs 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- AHOUBRCZNHFOSL-YOEHRIQHSA-N (+)-Casbol Chemical compound C1=CC(F)=CC=C1[C@H]1[C@H](COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-YOEHRIQHSA-N 0.000 description 1
- GJJFMKBJSRMPLA-HIFRSBDPSA-N (1R,2S)-2-(aminomethyl)-N,N-diethyl-1-phenyl-1-cyclopropanecarboxamide Chemical compound C=1C=CC=CC=1[C@@]1(C(=O)N(CC)CC)C[C@@H]1CN GJJFMKBJSRMPLA-HIFRSBDPSA-N 0.000 description 1
- XDIYNQZUNSSENW-UUBOPVPUSA-N (2R,3S,4R,5R)-2,3,4,5,6-pentahydroxyhexanal Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O XDIYNQZUNSSENW-UUBOPVPUSA-N 0.000 description 1
- WSEQXVZVJXJVFP-HXUWFJFHSA-N (R)-citalopram Chemical compound C1([C@@]2(C3=CC=C(C=C3CO2)C#N)CCCN(C)C)=CC=C(F)C=C1 WSEQXVZVJXJVFP-HXUWFJFHSA-N 0.000 description 1
- RTHCYVBBDHJXIQ-MRXNPFEDSA-N (R)-fluoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-MRXNPFEDSA-N 0.000 description 1
- ZEUITGRIYCTCEM-KRWDZBQOSA-N (S)-duloxetine Chemical compound C1([C@@H](OC=2C3=CC=CC=C3C=CC=2)CCNC)=CC=CS1 ZEUITGRIYCTCEM-KRWDZBQOSA-N 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 206010008874 Chronic Fatigue Syndrome Diseases 0.000 description 1
- 102100039205 Cytochrome P450 3A4 Human genes 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 208000011688 Generalised anxiety disease Diseases 0.000 description 1
- 206010019133 Hangover Diseases 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 206010049816 Muscle tightness Diseases 0.000 description 1
- KYYIDSXMWOZKMP-UHFFFAOYSA-N O-desmethylvenlafaxine Chemical compound C1CCCCC1(O)C(CN(C)C)C1=CC=C(O)C=C1 KYYIDSXMWOZKMP-UHFFFAOYSA-N 0.000 description 1
- AHOUBRCZNHFOSL-UHFFFAOYSA-N Paroxetine hydrochloride Natural products C1=CC(F)=CC=C1C1C(COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-UHFFFAOYSA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 208000036992 Psychogenic pain disease Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-N Sulfurous acid Chemical compound OS(O)=O LSNNMFCWUKXFEE-UHFFFAOYSA-N 0.000 description 1
- 239000006096 absorbing agent Substances 0.000 description 1
- 239000003655 absorption accelerator Substances 0.000 description 1
- 229940124532 absorption promoter Drugs 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000000674 adrenergic antagonist Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 102000030619 alpha-1 Adrenergic Receptor Human genes 0.000 description 1
- 108020004102 alpha-1 Adrenergic Receptor Proteins 0.000 description 1
- 229940109073 amrix Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 229960001058 bupropion Drugs 0.000 description 1
- SNPPWIUOZRMYNY-UHFFFAOYSA-N bupropion Chemical compound CC(C)(C)NC(C)C(=O)C1=CC=CC(Cl)=C1 SNPPWIUOZRMYNY-UHFFFAOYSA-N 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000007894 caplet Substances 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 208000022371 chronic pain syndrome Diseases 0.000 description 1
- 229960001653 citalopram Drugs 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000001351 cycling effect Effects 0.000 description 1
- VXEAYBOGHINOKW-UHFFFAOYSA-N cyclobenzaprine hydrochloride Chemical compound Cl.C1=CC2=CC=CC=C2C(=CCCN(C)C)C2=CC=CC=C21 VXEAYBOGHINOKW-UHFFFAOYSA-N 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 229960001623 desvenlafaxine Drugs 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- -1 dissolution retarder Substances 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 229960002866 duloxetine Drugs 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 201000003104 endogenous depression Diseases 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000010579 first pass effect Methods 0.000 description 1
- 229960002464 fluoxetine Drugs 0.000 description 1
- 229960004038 fluvoxamine Drugs 0.000 description 1
- CJOFXWAVKWHTFT-XSFVSMFZSA-N fluvoxamine Chemical compound COCCCC\C(=N/OCCN)C1=CC=C(C(F)(F)F)C=C1 CJOFXWAVKWHTFT-XSFVSMFZSA-N 0.000 description 1
- 208000029364 generalized anxiety disease Diseases 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- BCGWQEUPMDMJNV-UHFFFAOYSA-N imipramine Chemical compound C1CC2=CC=CC=C2N(CCCN(C)C)C2=CC=CC=C21 BCGWQEUPMDMJNV-UHFFFAOYSA-N 0.000 description 1
- 229960004801 imipramine Drugs 0.000 description 1
- 239000005414 inactive ingredient Substances 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 238000007919 intrasynovial administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- JEIPFZHSYJVQDO-UHFFFAOYSA-N iron(III) oxide Inorganic materials O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 1
- 239000008297 liquid dosage form Substances 0.000 description 1
- 210000003750 lower gastrointestinal tract Anatomy 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 238000002493 microarray Methods 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 229960000600 milnacipran Drugs 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 230000036651 mood Effects 0.000 description 1
- 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N p-hydroxybenzoic acid methyl ester Natural products COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 229960002296 paroxetine Drugs 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000002974 pharmacogenomic effect Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 229960002073 sertraline Drugs 0.000 description 1
- VGKDLMBJGBXTGI-SJCJKPOMSA-N sertraline Chemical compound C1([C@@H]2CC[C@@H](C3=CC=CC=C32)NC)=CC=C(Cl)C(Cl)=C1 VGKDLMBJGBXTGI-SJCJKPOMSA-N 0.000 description 1
- 230000008665 sleep physiology Effects 0.000 description 1
- 208000020685 sleep-wake disease Diseases 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 239000007916 tablet composition Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- UEUXEKPTXMALOB-UHFFFAOYSA-J tetrasodium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O UEUXEKPTXMALOB-UHFFFAOYSA-J 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 210000002438 upper gastrointestinal tract Anatomy 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 229960004688 venlafaxine Drugs 0.000 description 1
- PNVNVHUZROJLTJ-UHFFFAOYSA-N venlafaxine Chemical compound C1=CC(OC)=CC=C1C(CN(C)C)C1(O)CCCCC1 PNVNVHUZROJLTJ-UHFFFAOYSA-N 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161449838P | 2011-03-07 | 2011-03-07 | |
| PCT/US2012/027926 WO2012122193A1 (en) | 2011-03-07 | 2012-03-06 | Methods and compositions for treating depression using cyclobenzaprine |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| ES2773834T3 ES2773834T3 (es) | 2020-07-15 |
| ES2773834T5 true ES2773834T5 (es) | 2023-03-16 |
Family
ID=46796107
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES12755254T Active ES2773834T5 (es) | 2011-03-07 | 2012-03-06 | Métodos y composiciones para tratar la depresión usando ciclobenzaprina |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US11998516B2 (enExample) |
| EP (2) | EP2683245B2 (enExample) |
| JP (2) | JP2014507475A (enExample) |
| AU (4) | AU2012225548B2 (enExample) |
| CA (1) | CA2829200C (enExample) |
| CY (1) | CY1122998T1 (enExample) |
| DK (1) | DK2683245T4 (enExample) |
| ES (1) | ES2773834T5 (enExample) |
| FI (1) | FI2683245T4 (enExample) |
| HR (1) | HRP20200142T4 (enExample) |
| HU (1) | HUE048596T2 (enExample) |
| LT (1) | LT2683245T (enExample) |
| PL (1) | PL2683245T5 (enExample) |
| PT (1) | PT2683245T (enExample) |
| RS (1) | RS60240B2 (enExample) |
| SI (1) | SI2683245T2 (enExample) |
| SM (1) | SMT202000083T1 (enExample) |
| WO (1) | WO2012122193A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE037281T2 (hu) * | 2009-11-20 | 2018-08-28 | Tonix Pharma Holdings Ltd | Eljárás és készítmény poszt-traumás stressz rendellenesség tüneteinek kezelésére ciklobenzaprin alkalmazásával |
| US20110319389A1 (en) | 2010-06-24 | 2011-12-29 | Tonix Pharmaceuticals, Inc. | Methods and compositions for treating fatigue associated with disordered sleep using very low dose cyclobenzaprine |
| US11998516B2 (en) | 2011-03-07 | 2024-06-04 | Tonix Pharma Holdings Limited | Methods and compositions for treating depression using cyclobenzaprine |
| US9636408B2 (en) | 2013-03-15 | 2017-05-02 | Tonix Pharma Holdings Limited | Eutectic formulations of cyclobenzaprine hydrochloride and amitriptyline hydrochloride |
| WO2015150948A1 (en) * | 2014-03-29 | 2015-10-08 | Wockhardt Limited | Modified release solid oral pharmaceutical compositions of cyclobenzaprine or a salt thereof |
| CA2961822A1 (en) | 2014-09-18 | 2016-03-24 | Tonix Pharma Holdings Limited | Eutectic formulations of cyclobenzaprine hydrochloride |
| CN106890129A (zh) * | 2015-12-18 | 2017-06-27 | 健乔信元医药生技股份有限公司 | 环苄普林之延释剂型 |
| BR112020011345A2 (pt) * | 2017-12-11 | 2020-11-17 | Tonix Pharma Holdings Limited | tratamento com ciclobenzaprina para agitação, psicose e declínio cognitivo na demência e condições neurodegenerativas |
Family Cites Families (79)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3882246A (en) | 1971-05-21 | 1975-05-06 | Merck & Co Inc | Treatment of skeletal muscle disorders with cyclobenzaprine |
| US4968507A (en) | 1984-06-20 | 1990-11-06 | Merck & Co., Inc. | Controlled porosity osmotic pump |
| US5073543A (en) | 1988-07-21 | 1991-12-17 | G. D. Searle & Co. | Controlled release formulations of trophic factors in ganglioside-lipsome vehicle |
| FR2635461B1 (fr) | 1988-08-18 | 1992-01-17 | Adir | Utilisation de derives tricycliques pour l'obtention de medicaments destines au traitement du stress |
| US5120548A (en) | 1989-11-07 | 1992-06-09 | Merck & Co., Inc. | Swelling modulated polymeric drug delivery device |
| US5733566A (en) | 1990-05-15 | 1998-03-31 | Alkermes Controlled Therapeutics Inc. Ii | Controlled release of antiparasitic agents in animals |
| US5580578A (en) | 1992-01-27 | 1996-12-03 | Euro-Celtique, S.A. | Controlled release formulations coated with aqueous dispersions of acrylic polymers |
| SG47101A1 (en) | 1992-07-31 | 1998-03-20 | Us Bioscience | Crystalline amifostine compositions and methods for the preparation and use of same |
| US5591767A (en) | 1993-01-25 | 1997-01-07 | Pharmetrix Corporation | Liquid reservoir transdermal patch for the administration of ketorolac |
| US5439686A (en) | 1993-02-22 | 1995-08-08 | Vivorx Pharmaceuticals, Inc. | Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor |
| WO1994018954A1 (en) | 1993-02-22 | 1994-09-01 | Vivorx Pharmaceuticals, Inc. | Methods for in vivo delivery of biologics and compositions useful therefor |
| US6753006B1 (en) | 1993-02-22 | 2004-06-22 | American Bioscience, Inc. | Paclitaxel-containing formulations |
| US6537579B1 (en) | 1993-02-22 | 2003-03-25 | American Bioscience, Inc. | Compositions and methods for administration of pharmacologically active compounds |
| US6096331A (en) | 1993-02-22 | 2000-08-01 | Vivorx Pharmaceuticals, Inc. | Methods and compositions useful for administration of chemotherapeutic agents |
| US6749868B1 (en) | 1993-02-22 | 2004-06-15 | American Bioscience, Inc. | Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof |
| US5354566A (en) | 1993-06-02 | 1994-10-11 | Kraft General Foods, Inc. | Preparation of yeast-leavened dough crusts |
| IT1270594B (it) | 1994-07-07 | 1997-05-07 | Recordati Chem Pharm | Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida |
| US5834025A (en) | 1995-09-29 | 1998-11-10 | Nanosystems L.L.C. | Reduction of intravenously administered nanoparticulate-formulation-induced adverse physiological reactions |
| US6649186B1 (en) | 1996-09-20 | 2003-11-18 | Ethypharm | Effervescent granules and methods for their preparation |
| US20030077227A1 (en) | 1997-10-01 | 2003-04-24 | Dugger Harry A. | Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the central nervous system |
| WO1999018937A1 (en) | 1997-10-16 | 1999-04-22 | Merck & Co., Inc. | New cyclobenzaprine composition |
| JP2002514592A (ja) | 1998-05-14 | 2002-05-21 | アルザ コーポレイション | 抗うつ剤療法 |
| US6761903B2 (en) | 1999-06-30 | 2004-07-13 | Lipocine, Inc. | Clear oil-containing pharmaceutical compositions containing a therapeutic agent |
| US6248363B1 (en) | 1999-11-23 | 2001-06-19 | Lipocine, Inc. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
| US7374779B2 (en) | 1999-02-26 | 2008-05-20 | Lipocine, Inc. | Pharmaceutical formulations and systems for improved absorption and multistage release of active agents |
| US6267985B1 (en) | 1999-06-30 | 2001-07-31 | Lipocine Inc. | Clear oil-containing pharmaceutical compositions |
| US6383471B1 (en) | 1999-04-06 | 2002-05-07 | Lipocine, Inc. | Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents |
| US6309663B1 (en) | 1999-08-17 | 2001-10-30 | Lipocine Inc. | Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents |
| US6395788B1 (en) | 1999-08-13 | 2002-05-28 | Vela Pharmaceuticals, Inc. | Methods and compositions for treating or preventing sleep disturbances and associated illnesses using very low doses of cyclobenzaprine |
| WO2001012174A1 (en) | 1999-08-13 | 2001-02-22 | Vela Pharmaceuticals Inc. | Cyclobenzaprine for treating generalized anxiety disorder and compositions thereof |
| US6720001B2 (en) | 1999-10-18 | 2004-04-13 | Lipocine, Inc. | Emulsion compositions for polyfunctional active ingredients |
| WO2001089476A1 (en) | 2000-05-19 | 2001-11-29 | Npd Llc | Chewing gums, lozenges, candies, tablets, liquids, and sprays for efficient delivery of medications and dietary supplements |
| EP1441708B1 (en) | 2001-11-05 | 2009-04-08 | Krele Pharmaceuticals LLC | Compositions and methods for increasing compliance with therapies using aldehyde dehydrogenase inhibitors and treating alcoholism |
| US7659253B2 (en) | 2002-02-22 | 2010-02-09 | Shire Llc | Abuse-resistant amphetamine prodrugs |
| US7700561B2 (en) | 2002-02-22 | 2010-04-20 | Shire Llc | Abuse-resistant amphetamine prodrugs |
| US7105486B2 (en) | 2002-02-22 | 2006-09-12 | New River Pharmaceuticals Inc. | Abuse-resistant amphetamine compounds |
| EP1578719A4 (en) | 2002-10-25 | 2006-07-05 | Collegium Pharmaceutical Inc | P-HYDROXY-MILNACIPRAN STEREOISOMERS AND METHODS OF USING THE SAME |
| SI1585548T1 (sl) | 2002-12-09 | 2018-11-30 | Abraxis Bioscience, Llc | Sestave in metode odmerjanja farmakoloških sredstev |
| US8688385B2 (en) | 2003-02-20 | 2014-04-01 | Mayo Foundation For Medical Education And Research | Methods for selecting initial doses of psychotropic medications based on a CYP2D6 genotype |
| US20050059656A1 (en) | 2003-04-07 | 2005-03-17 | Cornell Research Foundation, Inc. | Compositions and methods for protecting against mitochondria component-mediated pathology |
| KR101159477B1 (ko) | 2003-05-29 | 2012-07-02 | 샤이어 엘엘씨 | 남용 방지성 암페타민 화합물 |
| BRPI0415683A (pt) | 2003-11-03 | 2006-12-19 | Warner Lambert Co | inibidores da reabsorção de norepinefrina para o tratamento de distúrbios do sistema nervoso central |
| US20050143350A1 (en) | 2003-11-19 | 2005-06-30 | Seed John C. | Combination drug therapy to treat obesity |
| EP1727520A2 (en) | 2003-12-09 | 2006-12-06 | Medcrystalforms, Llc | Method of preparation of mixed phase co-crystals with active agents |
| US7658945B2 (en) | 2004-02-17 | 2010-02-09 | Transcept Pharmaceuticals, Inc. | Compositions for delivering hypnotic agents across the oral mucosa and methods of use thereof |
| TW200531680A (en) | 2004-03-03 | 2005-10-01 | Merz Pharma Gmbh & Co Kgaa | Therapy using 1-aminocyclohexane derivatives for the treatment of behavioral disorders associated with alzheimer's disease |
| US8216610B2 (en) | 2004-05-28 | 2012-07-10 | Imaginot Pty Ltd. | Oral paracetamol formulations |
| US20070196364A1 (en) | 2004-07-27 | 2007-08-23 | Human Genome Sciences, Inc. | Pharmaceutical Formulation and Process |
| US7532935B2 (en) | 2005-07-29 | 2009-05-12 | Cyberonics, Inc. | Selective neurostimulation for treating mood disorders |
| US7994220B2 (en) | 2005-09-28 | 2011-08-09 | Cypress Bioscience, Inc. | Milnacipran for the long-term treatment of fibromyalgia syndrome |
| US20090069267A1 (en) | 2006-01-17 | 2009-03-12 | Abrams Daniel J | Central administration of stable formulations of therapeutic agents for cns conditions |
| US20080146672A1 (en) | 2006-12-08 | 2008-06-19 | Denton Marcia Marye | Topical Eutectic Anesthetic Composition for Oral or Dermal Tissue |
| EP2167066B1 (en) | 2007-05-07 | 2013-06-26 | Chelsea Therapeutics, Inc. | Droxidopa and pharmaceutical composition thereof for the treatment of attention deficit disorders |
| JP2010530874A (ja) | 2007-06-22 | 2010-09-16 | メルク・シャープ・エンド・ドーム・コーポレイション | ６，５−ピロロピペリジンタキキニン受容体アンタゴニスト |
| CA2707858A1 (en) | 2007-07-23 | 2009-01-29 | Synosia Therapeutics, Inc. | Treatment of post-traumatic stress disorder |
| US20090060983A1 (en) | 2007-08-30 | 2009-03-05 | Bunick Frank J | Method And Composition For Making An Orally Disintegrating Dosage Form |
| AU2008303129B2 (en) | 2007-09-25 | 2013-08-01 | Formulex Pharma Innovations Ltd. | Compositions comprising lipophilic active compounds and method for their preparation |
| US20100247649A1 (en) | 2007-10-30 | 2010-09-30 | Dr. Reddy's Laboratories Ltd. | Pharmaceutical formulations comprising telmisartan and hydrochlorothiazide |
| US20090148532A1 (en) | 2007-12-06 | 2009-06-11 | Venkatesh Gopi M | Preparation of controlled release skeletal muscle relaxant dosage forms |
| US8124126B2 (en) | 2008-01-09 | 2012-02-28 | Charleston Laboratories, Inc. | Pharmaceutical compositions |
| EP2244679A4 (en) | 2008-02-08 | 2013-10-09 | Qps Llc | NON-POLYMERIC COMPOSITIONS FOR CONTROLLED MEDICINAL PRODUCTION |
| US9314469B2 (en) | 2008-05-05 | 2016-04-19 | Tonix Pharma Holdings Limited | Method for treating neurocognitive dysfunction |
| JP5380909B2 (ja) | 2008-05-30 | 2014-01-08 | 株式会社ブリヂストン | 金型及び樹脂発泡成形品の成形方法 |
| US20100266682A1 (en) | 2008-12-10 | 2010-10-21 | Nipun Davar | Polyethylene glycol-coated sodium carbonate as a pharmaceutical excipient and compositions produced from the same |
| US20100247586A1 (en) | 2009-03-27 | 2010-09-30 | Andreas Hugerth | Multi-Portion Intra-Oral Dosage Form With Organoleptic Properties |
| EP2233134A1 (en) | 2009-03-27 | 2010-09-29 | McNeil AB | Multi-portion intra-oral dosage form with organoleptic properties |
| US20110070301A1 (en) | 2009-09-24 | 2011-03-24 | Luber Joseph R | Orally transformable tablets |
| HUE037281T2 (hu) | 2009-11-20 | 2018-08-28 | Tonix Pharma Holdings Ltd | Eljárás és készítmény poszt-traumás stressz rendellenesség tüneteinek kezelésére ciklobenzaprin alkalmazásával |
| US20110319389A1 (en) | 2010-06-24 | 2011-12-29 | Tonix Pharmaceuticals, Inc. | Methods and compositions for treating fatigue associated with disordered sleep using very low dose cyclobenzaprine |
| JP6355921B2 (ja) | 2010-09-01 | 2018-07-11 | トニックス ファーマスーティカルズ, インコーポレイテッドTONIX Pharmaceuticals, Inc. | コカイン嗜癖の治療 |
| US11998516B2 (en) | 2011-03-07 | 2024-06-04 | Tonix Pharma Holdings Limited | Methods and compositions for treating depression using cyclobenzaprine |
| ITMI20110558A1 (it) | 2011-04-06 | 2012-10-07 | Campiglio Consulting Srl | Composizione farmaceutica contenente ciclobenzaprina adatta alla somministrazione endonasale |
| SI2861223T1 (sl) | 2012-06-15 | 2023-01-31 | Tonix Pharma Holdings Limited | Sestavki in postopki za transmukozalno absorpcijo |
| WO2014071134A1 (en) | 2012-11-05 | 2014-05-08 | Emory University | 7,8-dihydoxyflavone and 7,8-substituted flavone derivatives, compositions, and methods related thereto |
| US9636408B2 (en) | 2013-03-15 | 2017-05-02 | Tonix Pharma Holdings Limited | Eutectic formulations of cyclobenzaprine hydrochloride and amitriptyline hydrochloride |
| EP3177286A4 (en) | 2014-07-18 | 2018-05-16 | Medipath Inc. | Compositions and methods for physiological delivery using cannabidiol |
| CA2961822A1 (en) | 2014-09-18 | 2016-03-24 | Tonix Pharma Holdings Limited | Eutectic formulations of cyclobenzaprine hydrochloride |
| BR112020011345A2 (pt) | 2017-12-11 | 2020-11-17 | Tonix Pharma Holdings Limited | tratamento com ciclobenzaprina para agitação, psicose e declínio cognitivo na demência e condições neurodegenerativas |
| EP4543427A1 (en) | 2022-06-21 | 2025-04-30 | Tonix Pharmaceuticals Holding Corp. | Cyclobenzaprine treatment for post-acute sequelae of (sars)-cov-2 infection (pasc) |
-
2012
- 2012-03-05 US US13/412,571 patent/US11998516B2/en active Active
- 2012-03-06 JP JP2013557811A patent/JP2014507475A/ja active Pending
- 2012-03-06 AU AU2012225548A patent/AU2012225548B2/en active Active
- 2012-03-06 HU HUE12755254A patent/HUE048596T2/hu unknown
- 2012-03-06 DK DK12755254.5T patent/DK2683245T4/da active
- 2012-03-06 HR HRP20200142TT patent/HRP20200142T4/hr unknown
- 2012-03-06 SI SI201231736T patent/SI2683245T2/sl unknown
- 2012-03-06 FI FIEP12755254.5T patent/FI2683245T4/fi active
- 2012-03-06 CA CA2829200A patent/CA2829200C/en active Active
- 2012-03-06 LT LTEP12755254.5T patent/LT2683245T/lt unknown
- 2012-03-06 WO PCT/US2012/027926 patent/WO2012122193A1/en not_active Ceased
- 2012-03-06 ES ES12755254T patent/ES2773834T5/es active Active
- 2012-03-06 SM SM20200083T patent/SMT202000083T1/it unknown
- 2012-03-06 PT PT127552545T patent/PT2683245T/pt unknown
- 2012-03-06 RS RS20200155A patent/RS60240B2/sr unknown
- 2012-03-06 PL PL12755254.5T patent/PL2683245T5/pl unknown
- 2012-03-06 EP EP12755254.5A patent/EP2683245B2/en active Active
- 2012-03-06 EP EP19214568.8A patent/EP3682885A1/en not_active Withdrawn
-
2016
- 2016-01-18 JP JP2016007041A patent/JP2016053095A/ja active Pending
- 2016-08-31 AU AU2016222412A patent/AU2016222412B2/en active Active
-
2018
- 2018-06-26 AU AU2018204633A patent/AU2018204633C1/en active Active
-
2020
- 2020-02-05 CY CY20201100112T patent/CY1122998T1/el unknown
- 2020-06-11 AU AU2020203874A patent/AU2020203874B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2773834T5 (es) | Métodos y composiciones para tratar la depresión usando ciclobenzaprina | |
| US10722478B2 (en) | Methods and compositions for treating fatigue associated with disordered sleep using very low dose cyclobenzaprine | |
| ES2649022T3 (es) | Procedimientos y composiciones para tratar los síntomas asociados con el trastorno de estrés postraumático con ciclobenzaprina | |
| ES2690061T3 (es) | Composiciones para tratar la enfermedad de Parkinson | |
| CA3161244A1 (en) | Treatment of amyotrophic lateral sclerosis | |
| ES2762113T3 (es) | Métodos de proporcionar terapia de pérdida de peso en pacientes con depresión mayor | |
| CN107660147A (zh) | 用于治疗帕金森病和相关障碍的组合物 | |
| WO2014119985A2 (es) | Composición farmacéutica con un inhibidor selectivo de la enzima fosfodiesterasa en forma de gel oral | |
| CN101677972A (zh) | 一种用于治疗神经变性疾病的奈拉美生的新组合物 | |
| WO1998024411A2 (en) | Method for oral administration of buspirone | |
| CN105919991A (zh) | 泽兰素在制备治疗抑郁症药物中的应用 | |
| CN107789354A (zh) | 预防和治疗抑郁症的化合物及其应用 | |
| Lorimer et al. | Cardiovascular disease | |
| HK40083948A (en) | A2-73 for treating angelman syndrome, williams syndrome smith-magenis syndrome and multiple sclerosis | |
| HK1176235A (en) | Methods and compositions for treating symptoms associated with post-traumatic stress disorder using cyclobenzaprine | |
| HK1176235B (en) | Methods and compositions for treating symptoms associated with post-traumatic stress disorder using cyclobenzaprine |